Common Contracts
13 similar Underwriting Agreement contracts by Home Loan Servicing Solutions, Ltd., Mirum Pharmaceuticals, Inc., Dermira, Inc., others
Impel NeuroPharma, Inc. [●] Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • September 7th, 2021 • Impel Neuropharma Inc • Pharmaceutical preparations • New York
Longboard Pharmaceuticals, Inc. [•] Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • March 8th, 2021 • Longboard Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
EX-1.1 2 d630873dex11.htm EX-1.1 Harpoon Therapeutics, Inc. [·] Shares Common Stock ($0.0001 par value per share) Underwriting Agreement New York, New York Citigroup Global Markets Inc. SVB Leerink LLC As Representatives of the several Underwriters...Underwriting Agreement • May 5th, 2020 • New York
Mirum Pharmaceuticals, Inc. [ 🌑 ] Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • January 6th, 2020 • Mirum Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Mirum Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [ 🌑 ] shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [ 🌑 ] additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I hereto other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires.
Mirum Pharmaceuticals, Inc. [●] Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • July 8th, 2019 • Mirum Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Mirum Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [●] shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [●] additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I hereto other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires.
Dermira, Inc. 9,811,321 Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • March 20th, 2019 • Dermira, Inc. • Pharmaceutical preparations • New York
Dermira, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.001 par value (“Common Stock”) of the Company set forth on Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth on Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to
Harpoon Therapeutics, Inc. [·] Shares Common Stock ($0.0001 par value per share) Underwriting AgreementUnderwriting Agreement • January 29th, 2019 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
ZOGENIX, INC. 4,750,000 Shares Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 30th, 2015 • Zogenix, Inc. • Pharmaceutical preparations • New York
Zogenix, Inc., a Delaware corporation (the “Company”), confirms its agreement with Leerink Partners LLC (“Leerink”), Stifel, Nicolaus & Company, Incorporated (“Stifel”) and each of the other Underwriters named in Schedule I hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Leerink and Stifel are acting as representatives (in such capacity, the “Representatives”), with respect to the issue and sale by the Company of 4,750,000 shares (the “Initial Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Initial Securities set forth in said Schedule I hereto, and with respect to the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of the 712,500 addi
RADIAN GROUP INC. (a Delaware corporation)Underwriting Agreement • May 13th, 2014 • Radian Group Inc • Surety insurance • New York
Radian Group Inc., a Delaware corporation (the “Company”), confirms its agreement with Goldman, Sachs & Co. (“Goldman Sachs”) and each of the other Underwriters names in Schedule A hereto (collectively, the “Underwriters”, which term shall also include any underwriter substituted as hereinafter provided in Section 12 hereof), for whom Goldman Sachs is acting as representative (in such capacity, the “Representative”), with respect to the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective principal amounts set forth in said Schedule A of $300,000,000 aggregate principal amount of the Company’s 5.500% Senior Notes due 2019 (the “Securities”). The Securities are to be issued pursuant to the provisions of a Senior Indenture, dated as of March 4, 2013 (the “Base Indenture”), as supplemented by the Second Supplemental Indenture, to be dated as of May 13, 2014 (the “Supplemental Indenture”, and together with the Base Indenture, the “In
EMERITUS CORPORATION (a Washington corporation) 7,973,600 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 18th, 2013 • Emeritus Corp\wa\ • Services-nursing & personal care facilities • New York
HOME LOAN SERVICING SOLUTIONS, LTD. [—] Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • December 7th, 2012 • Home Loan Servicing Solutions, Ltd. • Mortgage bankers & loan correspondents • New York
HOME LOAN SERVICING SOLUTIONS, LTD. [—] Ordinary Shares FORM OF UNDERWRITING AGREEMENTUnderwriting Agreement • September 5th, 2012 • Home Loan Servicing Solutions, Ltd. • Mortgage bankers & loan correspondents • New York
IDENIX PHARMACEUTICALS, INC. (a Delaware corporation) 6,460,672 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 30th, 2010 • Idenix Pharmaceuticals Inc • Pharmaceutical preparations • New York
Thomas Weisel Partners LLC as representative of the Underwriters named in Schedule A hereto, c/o Thomas Weisel Partners LLC One Montgomery Street, Suite 3700 San Francisco, CA 94104
